DK2171625T3 - Fremgangsmåde og anordning til at forebyggelse af hypoglykæmi - Google Patents
Fremgangsmåde og anordning til at forebyggelse af hypoglykæmi Download PDFInfo
- Publication number
- DK2171625T3 DK2171625T3 DK08825970.0T DK08825970T DK2171625T3 DK 2171625 T3 DK2171625 T3 DK 2171625T3 DK 08825970 T DK08825970 T DK 08825970T DK 2171625 T3 DK2171625 T3 DK 2171625T3
- Authority
- DK
- Denmark
- Prior art keywords
- tbg
- bbg
- patient
- insulin
- basal
- Prior art date
Links
- 238000000034 method Methods 0.000 title description 64
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 294
- 206010022489 Insulin Resistance Diseases 0.000 claims description 184
- 229940125396 insulin Drugs 0.000 claims description 148
- 102000004877 Insulin Human genes 0.000 claims description 146
- 108090001061 Insulin Proteins 0.000 claims description 146
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 119
- 239000008103 glucose Substances 0.000 claims description 119
- 208000013016 Hypoglycemia Diseases 0.000 claims description 87
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 83
- 239000008280 blood Substances 0.000 claims description 74
- 210000004369 blood Anatomy 0.000 claims description 74
- 230000002265 prevention Effects 0.000 claims description 48
- 150000001720 carbohydrates Chemical class 0.000 claims description 42
- 238000012937 correction Methods 0.000 claims description 36
- 230000009471 action Effects 0.000 claims description 22
- 230000001225 therapeutic effect Effects 0.000 claims description 22
- 230000009467 reduction Effects 0.000 claims description 11
- 230000008859 change Effects 0.000 claims description 6
- 235000014633 carbohydrates Nutrition 0.000 description 40
- 230000000422 nocturnal effect Effects 0.000 description 27
- 238000001802 infusion Methods 0.000 description 26
- 230000003247 decreasing effect Effects 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 238000005259 measurement Methods 0.000 description 9
- 238000004364 calculation method Methods 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 235000021074 carbohydrate intake Nutrition 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 238000004891 communication Methods 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 230000002641 glycemic effect Effects 0.000 description 5
- 230000002123 temporal effect Effects 0.000 description 5
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 238000004590 computer program Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 206010020997 Hypoglycaemia unawareness Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 235000011888 snacks Nutrition 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- 206010052093 Somogyi phenomenon Diseases 0.000 description 2
- 230000002567 autonomic effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 102000052651 Pancreatic hormone Human genes 0.000 description 1
- 101800001268 Pancreatic hormone Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 229940123452 Rapid-acting insulin Drugs 0.000 description 1
- 108010026951 Short-Acting Insulin Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001517 counterregulatory effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000004025 pancreas hormone Substances 0.000 description 1
- 229940032957 pancreatic hormone Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 235000012434 pretzels Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M2005/14208—Pressure infusion, e.g. using pumps with a programmable infusion control system, characterised by the infusion program
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M2005/14268—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body with a reusable and a disposable component
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
- A61M2005/1726—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure the body parameters being measured at, or proximate to, the infusion site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3546—Range
- A61M2205/3569—Range sublocal, e.g. between console and disposable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/201—Glucose concentration
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Claims (14)
1. Anordning til forebyggelse af hypoglykæmi, der omfatter: midler til modtagelse af et målblodglucose- (TBG) niveau svarende til et ønsket glucoseniveau i en patients krop i et forudbestemt tidsrum; midler til modtagelse af et sengetidsblodglucose- (BBG) niveau svarende til glucoseniveauet i patientens krop i alt væsentligt ved starten af det forudbestemte tidsrum; midler til modtagelse af et første sæt af parametre, der omfatter patientens insulinsensitivitet (IS), patientens forhold mellem carbohydrat og insulin (CIR) og patientens restinsulin (RI), hvilket RI svarer til niveauet af restinsulin i patientens krop i alt væsentligt ved starten af det forudbestemte tidsrum; midler til bestemmelse af et terapeutisk handlingsforløb ved anvendelse af niveauerne af TBG, BBG og det første sæt af parametre; og midler til administration af det terapeutiske handlingsforløb til patienten, kendetegnet ved, at det forudbestemte tidsrum er en fasteperiode, og ved at, hvis BBG<TBG og RI>0 eller hvis BBG>TBG og RI>(BBG-TBG)/IS, det terapeutiske handlingsforløb indbefatter mindst én af: anvisning til patienten om at indtage en beregnet mængde carbohydrater (CC); reduktion af patientens basalrate (BR) eller anvisning til patienten om at reducere BR; eller anvisning til patienten om at indtage en modificeret beregnet mængde carbohydrater og om at reducere BR.
2. Anordning ifølge krav 1, hvor, hvis BBG er mindre end TBG og patientens basalrate (BR) i alt væsentligt er konstant og RI i alt væsentligt er ubetydeligt, derefter for et hvilket som helst antal (n), reduktion af BR i et tidssegment (t) = n/BR til en reduceret BR' beregnes som: BR' = (IS'/IS)* BR, hvor IS'= IS-(TBG-BBG)/n.
3. Anordning ifølge krav 1, hvor, hvis BBG<TBG og RI > 0 og patientens basalrate (BR) i alt væsentligt er konstant, reduktion af BR i et tidssegment (t) = n/BR (hvor n er et positivt heltal) til en reduceret rate BR' beregnes som: BR'= (IS'/IS)*BR; hvor IS'= IS - ((TBG-( BBG - BGed))/n); og hvor BGed = IS*RI.
4. Anordning ifølge krav 1, hvor, hvis BBG>TBG og RI>(BBG-TBG)/IS, så CC = CIR*(RI + ((TBG-BBG)/IS)).
5. Anordning ifølge krav 1, hvor, hvis BBG<TBG, og RI i alt væsentligt er ubetydeligt, så CC = (CIR* (TBG-BBG))/IS.
6. Anordning ifølge krav 1, hvor, hvis BBGcTBG og RI>0, så CC = CIR*(RI + ((TBG-BBG)/IS)).
7. Anordning ifølge krav 1, hvor, hvis BR i alt væsentligt er ikke-konstant, reduktion af BR til en reduceret rate BR' opnås ved anvendelse af midler til at justering af den ikke-konstante bolusrate.
8. Anordning ifølge krav 1, hvor det terapeutiske handlingsforløb endvidere indbefatter én af: administration af en korrektionsbolus (CB) og anvisning til patienten om at administrere CB.
9. Anordning ifølge krav 8, hvor, hvis BBG>TBG og der i alt væsentligt ikke er noget RI, korrektionsbolussen beregnes som: CB = (BBG-TBG)/IS.
10. Anordning ifølge krav 8, hvor, hvis BBG>TBG og (BBG-TBG)/IS>RI, korrektionsbolussen beregnes som: CB = (BBG-TBG)/IS - RI.
11. Anordning ifølge krav 8, hvor, hvis ((BBG<TBG og RI>0) eller (BBG>TBG og RI>CB)) og BR i alt væsentligt ændres over tid, justering af BR til BR', hvor
hvor y er et tidsrum, hvori BR i alt væsentligt er konstant; hvor:
12. Anordning ifølge krav 11, hvor, hvis tidssegmentet (ti) er længere end et foruddefineret T, ændringen så begrænses til T ifølge nedenstående: a. m = T * basal (c) b. IS'i = IS - Δ /m- RI*IS/m c. hvis IS'i>0 end Basal'i = (IS'i/IS) * basal for tidssegment "T".
13. Anordning ifølge krav 1, hvor fasteperioden svarer til en periode natten over.
14. Anordning ifølge krav 1, hvor TBG er højere end en normal TBG.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93681007P | 2007-06-21 | 2007-06-21 | |
| PCT/US2008/007733 WO2009002455A1 (en) | 2007-06-21 | 2008-06-20 | Method and device for preventing hypoglycemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2171625T3 true DK2171625T3 (da) | 2018-11-19 |
Family
ID=39769076
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12177881.5T DK2518655T3 (da) | 2007-06-21 | 2008-06-20 | Anordning og fremgangsmåde til forebyggelse af hypoglykæmi |
| DK08825970.0T DK2171625T3 (da) | 2007-06-21 | 2008-06-20 | Fremgangsmåde og anordning til at forebyggelse af hypoglykæmi |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12177881.5T DK2518655T3 (da) | 2007-06-21 | 2008-06-20 | Anordning og fremgangsmåde til forebyggelse af hypoglykæmi |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10350354B2 (da) |
| EP (2) | EP2171625B1 (da) |
| JP (1) | JP2010530279A (da) |
| DK (2) | DK2518655T3 (da) |
| ES (2) | ES2767265T3 (da) |
| PL (1) | PL2518655T3 (da) |
| SI (1) | SI2518655T1 (da) |
| WO (1) | WO2009002455A1 (da) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080172026A1 (en) | 2006-10-17 | 2008-07-17 | Blomquist Michael L | Insulin pump having a suspension bolus |
| US6852104B2 (en) | 2002-02-28 | 2005-02-08 | Smiths Medical Md, Inc. | Programmable insulin pump |
| US8417311B2 (en) * | 2008-09-12 | 2013-04-09 | Optiscan Biomedical Corporation | Fluid component analysis system and method for glucose monitoring and control |
| EP3868284A1 (en) | 2007-10-10 | 2021-08-25 | Optiscan Biomedical Corporation | Fluid component analysis system and method for glucose monitoring and control |
| US7959598B2 (en) | 2008-08-20 | 2011-06-14 | Asante Solutions, Inc. | Infusion pump systems and methods |
| US20100174553A1 (en) * | 2008-12-24 | 2010-07-08 | Medtronic Minimed, Inc. | Diabetes Therapy Management System |
| EP2399205B1 (en) * | 2009-02-25 | 2020-04-08 | University Of Virginia Patent Foundation | Cgm-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
| ES2976564T3 (es) | 2011-02-01 | 2024-08-05 | Channel Medsystems Inc | Aparato para el tratamiento criogénico de una cavidad o luz del cuerpo |
| US11798685B2 (en) | 2012-05-15 | 2023-10-24 | James M. Minor | Diagnostic methods and devices for controlling acute glycemia |
| WO2013173499A2 (en) | 2012-05-15 | 2013-11-21 | Minor James M | Diagnostic methods and devices for monitoring chronic glycemia |
| CA2897925C (en) * | 2013-01-14 | 2017-05-30 | The Regents Of The University Of California | Daily periodic target-zone modulation in the model predictive control problem for artificial pancreas for type 1 diabetes applications |
| US9561324B2 (en) | 2013-07-19 | 2017-02-07 | Bigfoot Biomedical, Inc. | Infusion pump system and method |
| DK2865325T3 (da) | 2013-10-23 | 2018-02-19 | Hoffmann La Roche | Holder til at klæbe fast på huden til infusionspumpe eller kontinuerlig blodsukkermonitor med optisk indikationsorgan |
| WO2015100439A1 (en) | 2013-12-26 | 2015-07-02 | Tandem Diabetes Care, Inc. | Integration of infusion pump with remote electronic device |
| GB2523989B (en) | 2014-01-30 | 2020-07-29 | Insulet Netherlands B V | Therapeutic product delivery system and method of pairing |
| US9233204B2 (en) | 2014-01-31 | 2016-01-12 | Aseko, Inc. | Insulin management |
| US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
| JP6834488B2 (ja) * | 2014-10-08 | 2021-02-24 | 味の素株式会社 | 取得方法、評価装置、評価プログラムおよび評価システム |
| US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
| JP6989262B2 (ja) | 2014-10-27 | 2022-01-05 | アセコー インコーポレイテッド | 皮下外来患者管理 |
| US10737024B2 (en) | 2015-02-18 | 2020-08-11 | Insulet Corporation | Fluid delivery and infusion devices, and methods of use thereof |
| CA2993275C (en) | 2015-08-20 | 2022-06-21 | Aseko, Inc. | Diabetes management therapy advisor |
| US10293108B2 (en) * | 2015-08-21 | 2019-05-21 | Medtronic Minimed, Inc. | Infusion devices and related patient ratio adjustment methods |
| US10117992B2 (en) * | 2015-09-29 | 2018-11-06 | Medtronic Minimed, Inc. | Infusion devices and related rescue detection methods |
| EP3359072B1 (en) * | 2015-10-08 | 2021-03-17 | Channel Medsystems, Inc. | Exhaust collection bag for cryogenic treatment |
| WO2017123525A1 (en) | 2016-01-13 | 2017-07-20 | Bigfoot Biomedical, Inc. | User interface for diabetes management system |
| US10780223B2 (en) | 2016-01-14 | 2020-09-22 | Bigfoot Biomedical, Inc. | Adjusting insulin delivery rates |
| US10610643B2 (en) | 2016-01-14 | 2020-04-07 | Bigfoot Biomedical, Inc. | Occlusion resolution in medication delivery devices, systems, and methods |
| US12383166B2 (en) | 2016-05-23 | 2025-08-12 | Insulet Corporation | Insulin delivery system and methods with risk-based set points |
| US10765807B2 (en) | 2016-09-23 | 2020-09-08 | Insulet Corporation | Fluid delivery device with sensor |
| US11096624B2 (en) | 2016-12-12 | 2021-08-24 | Bigfoot Biomedical, Inc. | Alarms and alerts for medication delivery devices and systems |
| US10583250B2 (en) | 2017-01-13 | 2020-03-10 | Bigfoot Biomedical, Inc. | System and method for adjusting insulin delivery |
| EP3568862B1 (en) | 2017-01-13 | 2026-03-18 | Insulet Corporation | System and method for adjusting insulin delivery |
| US10500334B2 (en) | 2017-01-13 | 2019-12-10 | Bigfoot Biomedical, Inc. | System and method for adjusting insulin delivery |
| WO2018132765A1 (en) | 2017-01-13 | 2018-07-19 | Mazlish Bryan | Insulin delivery methods, systems and devices |
| US10758675B2 (en) | 2017-01-13 | 2020-09-01 | Bigfoot Biomedical, Inc. | System and method for adjusting insulin delivery |
| EP3568860B1 (en) | 2017-01-13 | 2025-12-10 | Insulet Corporation | Insulin delivery methods, systems and devices |
| USD928199S1 (en) | 2018-04-02 | 2021-08-17 | Bigfoot Biomedical, Inc. | Medication delivery device with icons |
| CN118750687A (zh) | 2018-05-04 | 2024-10-11 | 英赛罗公司 | 基于控制算法的药物输送系统的安全约束 |
| US12562251B1 (en) | 2018-05-09 | 2026-02-24 | Bigfoot Biomedical, Inc. | Computing architecture for assuring the provenance of medication therapy related parameters, and related systems, methods and devices |
| JP2022501139A (ja) | 2018-09-28 | 2022-01-06 | インスレット コーポレイション | 人工膵臓システム用活動モード |
| US11565039B2 (en) | 2018-10-11 | 2023-01-31 | Insulet Corporation | Event detection for drug delivery system |
| EP3877984A1 (en) | 2018-11-06 | 2021-09-15 | Universita' Degli Studi Di Padova | A real-time continuous glucose monitoring based method to trigger carbohydrates assumption to prevent/mitigate hypoglycemic events |
| USD920343S1 (en) | 2019-01-09 | 2021-05-25 | Bigfoot Biomedical, Inc. | Display screen or portion thereof with graphical user interface associated with insulin delivery |
| US11801344B2 (en) | 2019-09-13 | 2023-10-31 | Insulet Corporation | Blood glucose rate of change modulation of meal and correction insulin bolus quantity |
| AU2020351154A1 (en) | 2019-09-17 | 2022-03-31 | Cass Pharmaceuticals, Inc. | Subcutaneously injectable insulin formulations and methods of administration |
| US11935637B2 (en) | 2019-09-27 | 2024-03-19 | Insulet Corporation | Onboarding and total daily insulin adaptivity |
| US11957875B2 (en) | 2019-12-06 | 2024-04-16 | Insulet Corporation | Techniques and devices providing adaptivity and personalization in diabetes treatment |
| US11833329B2 (en) | 2019-12-20 | 2023-12-05 | Insulet Corporation | Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns |
| JP7512395B2 (ja) | 2020-01-06 | 2024-07-08 | インスレット コーポレイション | 持続する残差に基づく食事および／または運動行為の予測 |
| EP4100958A1 (en) | 2020-02-03 | 2022-12-14 | Insulet Corporation | Use of fuzzy logic in predicting user behavior affecting blood glucose concentration |
| US11551802B2 (en) | 2020-02-11 | 2023-01-10 | Insulet Corporation | Early meal detection and calorie intake detection |
| US11547800B2 (en) | 2020-02-12 | 2023-01-10 | Insulet Corporation | User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system |
| US11986630B2 (en) | 2020-02-12 | 2024-05-21 | Insulet Corporation | Dual hormone delivery system for reducing impending hypoglycemia and/or hyperglycemia risk |
| US11324889B2 (en) | 2020-02-14 | 2022-05-10 | Insulet Corporation | Compensation for missing readings from a glucose monitor in an automated insulin delivery system |
| US12495994B2 (en) | 2020-02-20 | 2025-12-16 | Insulet Corporation | Meal bolus subcategories in model based insulin therapy |
| US11607493B2 (en) | 2020-04-06 | 2023-03-21 | Insulet Corporation | Initial total daily insulin setting for user onboarding |
| AU2021299214A1 (en) * | 2020-07-02 | 2023-02-23 | Enable Injections, Inc. | Medical fluid injection apparatus and method with reusable patch |
| US12121700B2 (en) | 2020-07-22 | 2024-10-22 | Insulet Corporation | Open-loop insulin delivery basal parameters based on insulin delivery records |
| US11684716B2 (en) | 2020-07-31 | 2023-06-27 | Insulet Corporation | Techniques to reduce risk of occlusions in drug delivery systems |
| US12569619B2 (en) | 2020-09-21 | 2026-03-10 | Insulet Corporation | Techniques for determining automated insulin delivery dosages |
| EP4221588A1 (en) | 2020-09-30 | 2023-08-09 | Insulet Corporation | Secure wireless communications between a glucose monitor and other devices |
| US12128215B2 (en) | 2020-09-30 | 2024-10-29 | Insulet Corporation | Drug delivery device with integrated optical-based glucose monitor |
| US11160925B1 (en) | 2021-01-29 | 2021-11-02 | Insulet Corporation | Automatic drug delivery system for delivery of a GLP-1 therapeutic |
| US12431229B2 (en) | 2021-03-10 | 2025-09-30 | Insulet Corporation | Medicament delivery device with an adjustable and piecewise analyte level cost component to address persistent positive analyte level excursions |
| US11904140B2 (en) | 2021-03-10 | 2024-02-20 | Insulet Corporation | Adaptable asymmetric medicament cost component in a control system for medicament delivery |
| US12592306B2 (en) | 2021-04-28 | 2026-03-31 | Insulet Corporation | Devices and methods for initialization of drug delivery devices using measured analyte sensor information |
| US12496398B2 (en) | 2021-05-28 | 2025-12-16 | Insulet Corporation | Threshold based automatic glucose control response |
| US12406760B2 (en) | 2021-06-07 | 2025-09-02 | Insulet Corporation | Exercise safety prediction based on physiological conditions |
| US12514980B2 (en) | 2021-06-30 | 2026-01-06 | Insulet Corporation | Adjustment of medicament delivery by a medicament delivery device based on menstrual cycle phase |
| US12521486B2 (en) | 2021-07-16 | 2026-01-13 | Insulet Corporation | Method for modification of insulin delivery during pregnancy in automatic insulin delivery systems |
| EP4409581A1 (en) | 2021-09-27 | 2024-08-07 | Insulet Corporation | Techniques enabling adaptation of parameters in aid systems by user input |
| US11439754B1 (en) | 2021-12-01 | 2022-09-13 | Insulet Corporation | Optimizing embedded formulations for drug delivery |
| EP4243030A1 (en) | 2022-03-09 | 2023-09-13 | Insulet Corporation | Adjusting medicament delivery parameters in an open loop medicament delivery mode |
| US20230330334A1 (en) * | 2022-04-18 | 2023-10-19 | Luna Health, Inc. | Systems, devices and related methods of insulin management for delivering insulin during a fasting period |
| CN120457493A (zh) | 2023-01-06 | 2025-08-08 | 英赛罗公司 | 自动或手动启动的随餐推注输送及随后的自动安全约束放宽 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6554798B1 (en) * | 1998-08-18 | 2003-04-29 | Medtronic Minimed, Inc. | External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities |
| US6544212B2 (en) * | 2001-07-31 | 2003-04-08 | Roche Diagnostics Corporation | Diabetes management system |
| JP2007525241A (ja) | 2003-04-18 | 2007-09-06 | インシュレット コーポレイション | 注入ポンプ用リモコンのためのユーザーインターフェース及びそれの使用方法 |
| US20070078314A1 (en) | 2005-09-30 | 2007-04-05 | Grounsell Richard L | System and method for measuring and predicting insulin dosing rates |
| EP1955240B8 (en) | 2005-11-08 | 2016-03-30 | Bigfoot Biomedical, Inc. | Method for manual and autonomous control of an infusion pump |
| EP1993637A2 (en) | 2006-02-15 | 2008-11-26 | Medingo Ltd. | Systems and methods for sensing analyte and dispensing therapeutic fluid |
| US20080172031A1 (en) * | 2006-10-17 | 2008-07-17 | Blomquist Michael L | Insulin pump having correction factors |
| LT3632488T (lt) | 2006-12-22 | 2023-07-25 | Roche Diabetes Care Gmbh | Terapinio skysčio nuolatinio tiekimo prietaisas |
-
2008
- 2008-06-20 ES ES12177881T patent/ES2767265T3/es active Active
- 2008-06-20 DK DK12177881.5T patent/DK2518655T3/da active
- 2008-06-20 DK DK08825970.0T patent/DK2171625T3/da active
- 2008-06-20 EP EP08825970.0A patent/EP2171625B1/en active Active
- 2008-06-20 US US12/143,611 patent/US10350354B2/en active Active
- 2008-06-20 JP JP2010513260A patent/JP2010530279A/ja active Pending
- 2008-06-20 WO PCT/US2008/007733 patent/WO2009002455A1/en not_active Ceased
- 2008-06-20 SI SI200832108T patent/SI2518655T1/sl unknown
- 2008-06-20 PL PL12177881T patent/PL2518655T3/pl unknown
- 2008-06-20 ES ES08825970.0T patent/ES2693432T3/es active Active
- 2008-06-20 EP EP12177881.5A patent/EP2518655B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2171625A1 (en) | 2010-04-07 |
| PL2518655T3 (pl) | 2020-05-18 |
| EP2518655A3 (en) | 2013-01-09 |
| US10350354B2 (en) | 2019-07-16 |
| US20090030398A1 (en) | 2009-01-29 |
| SI2518655T1 (sl) | 2020-02-28 |
| EP2518655A2 (en) | 2012-10-31 |
| EP2171625B1 (en) | 2018-10-10 |
| ES2767265T3 (es) | 2020-06-17 |
| JP2010530279A (ja) | 2010-09-09 |
| DK2518655T3 (da) | 2020-02-03 |
| EP2518655B1 (en) | 2019-11-20 |
| WO2009002455A1 (en) | 2008-12-31 |
| ES2693432T3 (es) | 2018-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2171625B1 (en) | Method and device for preventing hypoglycemia | |
| US20230125668A1 (en) | Systems for determining insulin on board and recommending insulin therapy, and related methods | |
| DK2174128T3 (da) | Fremgangsmåde og anordning til evaluering af carbohydrat-til-insulin-forhold | |
| US10369281B2 (en) | Devices, systems and methods for adjusting fluid delivery parameters | |
| EP2350894B1 (en) | Methods and devices for tailoring a bolus delivery pattern | |
| DK2167168T3 (da) | Individualiseret basalt insulinindgivelsessystem | |
| US8845613B2 (en) | Bolus dose determination for a therapeutic fluid dispensing system | |
| US8439897B2 (en) | Assessing residual insulin time | |
| WO2009138984A2 (en) | Device and method for alleviating postprandial hyperglycemia | |
| AU2008227836A1 (en) | User interface for selecting bolus doses in a drug delivery device | |
| EP2230991A1 (en) | System and method for glycemic control | |
| US8911423B2 (en) | Systems and methods for glycemic control during pump disconnection | |
| Bezabeh et al. | Selected medical devices used to manage diabetes mellitus |